Project Grant R01NS144331
Award Date 8/1/25
Completion Date 7/31/30
Dollars Obligated $603K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Chapel Hill, NC 27599, USA
Similar Awards
- This Cooperative Agreement award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, is focused on developing a genome editor therapy for Angelman Syndrome, a severe neurodevelopmental disorder. The $1,508,248 award to the University of North Carolina at Chapel Hill will fund a 2-year Discovery (UG3) phase to identify and validate lead AAV-nCas9 vectors that...
- This $233,250 Project Grant awarded by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) supports the development and evaluation of a highly sensitive luciferase-based biosensor to quantify endogenous UBE3A ubiquitin ligase activity in cells and the brain. The University of North Carolina at Chapel Hill will conduct this research from March 2025 through February 2027, with the...
- This Project Grant award of $120,756 from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) supports research at the University of North Carolina at Chapel Hill to investigate the role of UBE3A isoforms in seizure susceptibility associated with Angelman Syndrome (AS). The research aims to establish the contribution of the UBE3A isoforms to AS-related seizures using seizure...
- The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $339,999 Project Grant under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) to Couragene, Inc., a for-profit organization located in Edison, New Jersey. The grant supports the development of a novel, chemically modified ribonucleoprotein (CRNP) delivery system for CRISPR-based gene editing to treat Angelman syndrome, a neurogenetic disorder. The project aims to optimize...
- This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, provides $427,625 to the University of Wisconsin System for research to systematically identify differentially ubiquitinated proteins, potentially UBE3A substrates, in UBE3A model mice in different cell types (excitatory and inhibitory neurons) at different developmental stages. The...
- This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) will lay the foundation for developing a molecular therapy for ADNP syndrome. The $395,009 award to the University of California, Davis will fund research to: 1) test the mechanism of action of antisense oligonucleotides (ASOs) that can increase ADNP protein expression in human neurons, and 2)...
- This Project Grant award, valued at $481,250.00 and provided by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, aims to develop a synthetic biological system to manipulate subcellular RNAs and proteins in growth cones or synapses of subtype- and context-specific neurons. The goal is to enable unique forms of subcellular functional investigation in subtype- and...
- This Project Grant award, funded by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, aims to explore the relationship between misexpression of the UBE3A gene and altered neural circuit dynamics that impact motor function. The $587,904 award, provided from August 2025 through May 2030, will enable researchers at the University of North Carolina at Chapel Hill to use...
- This $147,486 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) supports research to understand the disease mechanism and develop gene therapy for a common and understudied STXBP1 missense variant that causes severe developmental and epileptic encephalopathy. The applicant has established a mouse model that recapitulates key neurological symptoms of this...
- This federal Project Grant award, funded by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, aims to develop a non-viral gene-editing therapy using lipid nanoparticle (LNP)/mRNA complexes to correct UBE3A gene overexpression in neural stem progenitor cells during fetal brain development. The $654,339 award to the University of California, Davis will support research to...